CalciMedica's Groundbreaking Presentations at Medical Conferences
CalciMedica's Acceptance of Abstracts for Important Presentations
CalciMedica Inc. (NASDAQ: CALC) is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies targeting calcium release-activated calcium (CRAC) channels. It is focused on therapies that address acute and chronic inflammatory and immunologic diseases. Recently, the company announced significant achievements regarding upcoming presentations at notable medical meetings.
Poster Presentation at Digestive Disease Week
CalciMedica's abstract has been accepted for a poster presentation at the esteemed Digestive Disease Week (DDW) 2025. This event will take place from May 3 to May 6, bringing together professionals in the digestive disease community.
Details of the Poster Presentation
The poster presentation will focus on critical findings related to patients diagnosed with Acute Pancreatitis (AP) and the accompanying Systemic Inflammatory Response Syndrome (SIRS). The study presents evidence indicating these patients show a larger volume of distribution compared to healthy volunteers, which is promising for future treatment approaches.
Who Will Present?
This vital presentation will be delivered by Kenneth A. Stauderman, Ph.D., who serves as CalciMedica's co-Founder and Chief Scientific Officer. His expertise will contribute significantly to the discussion of clinical acute pancreatitis management during this session.
Oral Presentation at ASN Conference
Additionally, Sudarshan Hebbar, M.D., the Chief Medical Officer of CalciMedica, will present at the American Society of Nephrology (ASN) 3rd Acute Kidney Injury: From Bench to Bedside Conference.
Insights from Clinical Trials
Dr. Hebbar will share insights from his experiences with the design of AKI clinical trials. This presentation aims to shed light on the intricacies involved in effective trial methodologies and the progress regarding acute kidney injuries. It will take place on Tuesday, May 6, from 8:00 to 10:00 a.m. ET.
Panel Discussion on Non-Academic Careers
Furthermore, Dr. Hebbar will also participate in a panel discussion that addresses non-academic careers in science, emphasizing diversity and career paths that extend beyond traditional academia.
Details of the Panel Discussion
This engaging panel will occur on Wednesday, May 7, from 4:00 to 4:30 p.m. ET, and aims to enlighten attendees about various career trajectories and opportunities available in the scientific field.
About CalciMedica
CalciMedica is committed to advancing treatments for inflammatory and immunologic diseases. Their proprietary technology focuses on inhibiting CRAC channels, which plays a pivotal role in modulating immune responses. This innovative approach holds the potential to safeguard against tissue damage associated with life-threatening conditions that currently lack effective therapies.
The company's lead candidate, Auxora™, has shown positive outcomes in multiple clinical trials, demonstrating promise for patients suffering from serious medical conditions. Noteworthy trials include the Phase 2b trial (CARPO), specifically targeting acute pancreatitis and SIRS.
Clinical Trial Landscape
CalciMedica has recently concluded a Phase 2 trial (CARDEA), focusing on COVID pneumonia, and is actively engaged in further trials including KOURAGE and CRSPA. These trials aim to understand the effects of their treatments on various conditions, including acute kidney injury and pediatric patients with specific needs.
Contact and Further Information
For additional details on these presentations and ongoing initiatives, please visit CalciMedica's website to explore their medical events and studies. Their journey represents a commitment to excellence in medical research and patient care.
Frequently Asked Questions
What posts will CalciMedica present at the DDW event?
CalciMedica will present research on patients with Acute Pancreatitis and their larger volume of distribution compared to healthy volunteers.
Who will represent CalciMedica at the ASN conference?
Dr. Sudarshan Hebbar, the Chief Medical Officer, will deliver insights and participate in discussions.
When is the ASN conference presentation scheduled?
The oral presentation is scheduled for May 6 from 8:00 to 10:00 a.m. ET.
What topics will the panel discussion cover?
The panel discussion will focus on non-academic careers in science and diverse career pathways.
Where can I find more information about CalciMedica's clinical trials?
More information can be found on CalciMedica's investor relations webpage detailing their medical events and publications.
About The Author
Contact Logan Wright privately here. Or send an email with ATTN: Logan Wright as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.